Among people on osteoporosis medication, loss of appendicular or total body lean mass is an independent risk factor for hip and major osteoporotic fractures
Authors' conclusion
Loss of lean mass is associated with increased fracture risk among individuals on anti-osteoporosis medication.
Study context
- Population
- Individuals ≥ 40 years of age with two DXA assessments ≥ 1 year apart and minimum 0.5 years of observation37% on osteoporosis medication
- Participants
- 21,249 individuals
- Exposure
- Per SD of prior appendicular lean mass (ALM) or total body lean mass (TBLM) loss
- Outcome
- Time to first incident MOF and hip fracture
Methodological detailslinked to population-based data, Cox regression, adjusted for fracture risk, osteoporosis medication as interaction term and stratification
- Linked to population-based data
- Cox regression
- Adjusted for fracture risk
- Osteoporosis medication as interaction term and stratification
Main finding
As reported in the abstract
Major osteoporotic fracture (MOF), prior ALM loss: HR per SD
1.09 (1.04-1.15) (95% CI)
MOF, prior TBLM loss: HR per SD
1.09 (1.42-1.14) (95% CI)
Hip fracture, prior ALM loss: HR per SD
1.22 (1.12-1.33) (95% CI)
Hip fracture, prior TBLM loss: HR per SD
1.26 (1.16-1.38) (95% CI)
Observational data: associations, not effects.
Further findings
Interaction with anti-osteoporosis medication use
- No interactions with anti-osteoporosis medication use
- all p > 0.3
Restricted to people on anti-osteoporosis medication, per SD ALM or TBLM loss
- Increased MOF risk
- 8-9%
- Increased hip fracture risk
- 18-23%
Original publication
Among people on osteoporosis medication, loss of appendicular or total body lean mass is an independent risk factor for hip and major osteoporotic fractures. Osteoporos Int. Published 25 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →